deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 5-arm NCT04041050

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

A Phase 1 Open-Label Study Evaluating the Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Myeloproliferative Neoplasm Subjects

Sponsor: AbbVie

Conditions Myeloproliferative Neoplasm
Interventions Celecoxib Navitoclax Ruxolitinib
Updated 26 times since 2019 Last updated: Feb 12, 2025 Started: Nov 8, 2019 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04041050, this PHASE1 trial focuses on Myeloproliferative Neoplasm and remains ongoing. Sponsored by AbbVie, it has been updated 26 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~May 2020 · 6 months · monthly snapshot~May 2020 – ~Sep 2020 · 4 months · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Dec 2022 · 2 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Mar 2023 · 59 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

26 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Mar 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Jun 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

▶ Show 21 earlier versions

  1. Apr 2023 — Jun 2023 [monthly]

    Recruiting PHASE1

  2. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE1

  3. Jan 2023 — Mar 2023 [monthly]

    Recruiting PHASE1

  4. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE1

  5. Oct 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

  6. Sep 2022 — Oct 2022 [monthly]

    Recruiting PHASE1

  7. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  8. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  9. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

  10. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE1

  11. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE1

  12. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE1

  13. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE1

  14. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  15. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE1

  16. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  17. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  18. Sep 2020 — Nov 2020 [monthly]

    Recruiting PHASE1

  19. May 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

  20. Nov 2019 — May 2020 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  21. Sep 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Belgrade, Serbia , Berlin, Germany , Brescia, Italy , Bunkyo-ku, Japan , Canton, United States , Cheltenham, United Kingdom , Chicago, United States , Chuo-shi, Japan , Detroit, United States and 32 more locations